Across TCGA pan-cancer cohorts, KRTAP5-11 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KRTAP5-11 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in thyroid carcinoma (THCA), where higher KRTAP5-11 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KRTAP5-11 expression acts as an unfavorable survival marker.
THCA, BLCA, and ESCA are the cancer types where KRTAP5-11 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.